TFF Pharmaceuticals, Inc.

Equities

TFFP

US87241J2033

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 11:46:54 23/05/2024 pm IST			5-day change	1st Jan Change
2.11 ^USD	-3.21%		-2.31%	-69.94%

06:44pm	TFF Pharmaceuticals, Leidos to Advance Biodefense Countermeasures Into Preclinical Testing	MT
01:00pm	TFF Pharmaceuticals, Inc. and Leidos to Advance Next-Generation Biodefense Countermeasures Under the DARPA PPB Program into Preclinical Testing	CI

TFF Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022

March 01, 2023 at 01:36 am IST

TFF Pharmaceuticals, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 31.77 million compared to USD 31.04 million a year ago. Basic loss per share from continuing operations was USD 26.5 compared to USD 31.25 a year ago.

Latest news about TFF Pharmaceuticals, Inc.

TFF Pharmaceuticals, Leidos to Advance Biodefense Countermeasures Into Preclinical Testing	10:14pm	MT
TFF Pharmaceuticals, Inc. and Leidos to Advance Next-Generation Biodefense Countermeasures Under the DARPA PPB Program into Preclinical Testing	04:30pm	CI
TFF Pharmaceuticals Advances Influenza Vaccine Candidates Into Preclinical Testing	20/05	MT
Tff Pharmaceuticals, Inc. Provides Update on Tacrolimus Inhalation Powder (Tff Tac) Phase 2 Trial for the Prevention of Lung Transplant Rejection	15/05	CI
TFF Pharmaceuticals Prices $4.8 Million Public Offering; Shares Down Pre-Bell	30/04	MT
TFF Pharmaceuticals, Inc. Makes Available Phase 2 Data from Tacrolimus Inhalation Powder for Prevention of Lung Transplant Rejection Presented at Recent ISHLT Annual Meeting	29/04	CI
TFF Pharmaceuticals, Inc. Announces Additional Positive Data from the Tacrolimus Inhalation Powder (TFF Tac) Phase 2 Trial Following Oral Presentation At the Ishlt 44Th Annual Late-Breaking Clinical Science Abstract Sessions	15/04	CI
TFF Pharmaceuticals Files Equities Shelf	08/04	MT
Earnings Flash (TFFP) TFF PHARMACEUTICALS Reports Q4 Revenue $114.3M	29/03	MT
TFF Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	29/03	CI
TFF Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/03	CI
Roth MKM Cuts TFF Pharmaceuticals' Price Target to $44 From $56, Maintains Buy Rating	28/03	MT
Transcript : TFF Pharmaceuticals, Inc. - Special Call	28/03
TFF Pharmaceuticals, Inc. Announces Updated Data from the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (Tff VORI) Clinical Programs	28/03	CI
TFF Pharmaceuticals Sells Stock in Registered Direct Offering	20/03	MT
TFF Pharmaceuticals, Inc. Announces Update on Clinical Programs	20/03	CI
TFF Pharmaceuticals, Inc. to Present Data from Phase 2 Trial of Voriconazole Inhalation Powder for the Treatment of Invasive Pulmonary Aspergillosis At the 11Th Advances Against Aspergillosis & Mucormycosis & Mucromycosis Conference	24/01	CI
Certain Warrants of TFF Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 31-DEC-2023.	31/12	CI
Certain Options of TFF Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 31-DEC-2023.	31/12	CI
Certain Common Stock of TFF Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 31-DEC-2023.	31/12	CI
Transcript : TFF Pharmaceuticals, Inc. - Special Call	19/12
TFF Pharmaceuticals, Inc. Announces Positive Initial Data from Ongoing Phase 2 Trials of TFF VORI and TFF TAC	19/12	CI
TFF Pharmaceuticals, Inc. Appoints Thomas B. King to Board of Directors	14/12	CI
TFF Pharmaceuticals, Inc. Appoints Michael Patane to its Board of Directors and Compensation Committee	30/11	CI
TFF Pharmaceuticals, Inc. Appoints Catherine Lee to its Board of Directors and Nominating & Corporate Governance Committee	30/11	CI

Chart TFF Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

TFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaging patented rapid freezing technology to develop and transform medicine into potent dry powder. It is focused on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform. Its TFF technology platform has an applicability to convert any drug, including vaccines, small and large molecules, and biologics, into a dry powder for inhalation, or for topical delivery to the eyes, nose and the skin. TFF Pharmaceuticals has two lead drug candidates in the clinic: TFF TAC (Tacrolimus Inhalation Powder) and TFF VORI (Voriconazole Inhalation Powder). TFF TAC is an inhaled dry powder formulation of tacrolimus, for the prophylaxis of organ rejection in patients receiving lung transplants, in combination with other immunosuppressants. TFF VORI is an inhaled dry powder formulation of voriconazole, for the treatment and prophylaxis of invasive pulmonary aspergillosis.

Sector

Biotechnology & Medical Research

Calendar

04/06/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for TFF Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.18 USD

Average target price

17 USD

Spread / Average Target

+679.82%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
TFF PHARMACEUTICALS, INC.	-69.94%	6.75M
MODERNA, INC.	+63.39%	62.59B
IQVIA HOLDINGS INC.	-1.74%	41.18B
LONZA GROUP AG	+44.76%	40.29B
CELLTRION, INC.	-8.93%	27.9B
ICON PUBLIC LIMITED COMPANY	+12.63%	26.21B
ALNYLAM PHARMACEUTICALS, INC.	-21.98%	19.09B
BIO-TECHNE CORPORATION	+4.23%	13.08B
UNITED THERAPEUTICS CORPORATION	+25.71%	12.26B
MEDPACE HOLDINGS, INC.	+27.88%	12.05B

Other Biotechnology & Medical Research